Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5 Suppl
pubmed:dateCreated
1998-1-27
pubmed:abstractText
The myelopoietic growth factors, in particular G-CSF and GM-CSF have been available for clinical use for only a few years but they have already profoundly affected the management of chemotherapy-induced neutropenia, the use of dose-intensive chemotherapy regimens, and the practice and safety of autologous stem cell transplantation. While these growth factors have rapidly been introduced as routine agents in the management of cancer patients, they have continued to generate a considerable amount of basic research on the biology of hematopoiesis as well as on the growth regulation of normal and tumor cells. One attractive possibility offered by growth factors is to protect hemopoietic stem and progenitor cells from the toxic effects of chemotherapy, while not diminishing its anti-tumor action. Any means of preferentially and reversibly suppressing the proliferation of normal hemopoietic stem and progenitor cell while leaving unmodified the proliferation of tumor cells and their susceptibility to chemotherapy, could potentially optimize treatment efficacy. In the present paper, we have briefly discussed the possibility to use the myeloid growth factors as myeloprotective agents in the context of drug-intensified chemotherapy on the basis of the results obtained during some clinical trials recently conducted in patients with advanced cancer.
pubmed:language
ita
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0300-8916
pubmed:author
pubmed:issnType
Print
pubmed:volume
83
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
S3-7
pubmed:dateRevised
2008-12-12
pubmed:meshHeading
pubmed:articleTitle
[Novel ways of using hemopoietic growth factors].
pubmed:affiliation
Università e IRCCS San Matteo, Pavia, Italy. danova@mbox.medit.it
pubmed:publicationType
Journal Article, English Abstract, Review